Philip Morris International (NYSE:PM) is back in focus after the U.S. Food and Drug Administration authorized modified risk claims for 20 ZYN nicotine pouch variants, marking a first for this product category and a key regulatory milestone.

Philip Morris International’s share price has responded positively to the FDA’s decision, with a 1-day share price return of 2.58% and a 90-day share price return of 15.29%. The 5-year total shareholder return of 134.06% points to strong longer term momentum.

If this kind of regulatory catalyst has caught your attention, it may be worth scanning other potential beneficiaries of structural shifts by checking out 20 top founder-led companies

With Philip Morris International now up 15.3% over 90 days and trading at $182.27, yet sitting roughly 7% below the average analyst target and at an intrinsic value premium, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 5.6% Undervalued

On the most followed narrative, Philip Morris International’s fair value of $193.14 sits above the last close at $182.27, which puts today’s price at a modest discount to those assumptions.

The accelerating global adoption of smoke-free alternatives, driven by increasing health awareness and regulatory moves away from combustibles, is fueling strong double-digit volume and margin growth in PMI's IQOS, ZYN, and VEEV platforms. This secular shift enables the company to capture new consumer segments, expand its addressable market, and structurally boost net revenues and operating margins over time.

Want to understand why this smoke free pivot supports a higher fair value than today’s share price? The narrative focuses on revenue mix shifts, margin uplift and a richer profit multiple. Curious which assumptions really carry the model? The full breakdown connects those moving parts in detail.

Result: Fair Value of $193.14 (UNDERVALUED)

However, the picture for Philip Morris International is not one way. Potential tax and regulatory changes, or a slowdown in smoke free product uptake, are both capable of challenging this narrative.

Another View: Philip Morris International Looks Expensive On Earnings

While the most popular narrative frames Philip Morris International as 5.6% undervalued, the current P/E of 25.7x tells a stricter story. It sits above the Global Tobacco industry at 12x, the peer average at 23.5x, and even its own fair ratio of 25.2x. This points to limited valuation cushion if sentiment cools.

This kind of gap can close in more than one way, so the real question is whether you think earnings can grow into this premium faster than the market adjusts the multiple.

Next Steps

With Philip Morris International attracting both enthusiasm and caution, it makes sense to move quickly and review the data yourself rather than rely on any single narrative. To better understand the balance between potential upside and key risks, take a closer look at the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Philip Morris International?

If you are serious about building a stronger portfolio, do not stop with Philip Morris International. Use the Simply Wall St Screener to uncover more focused opportunities.

• Target potential bargains by scanning companies that trade below fair value with the 42 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks with robust payouts through the 7 dividend fortresses.
• Prioritize resilience by focusing on companies with prudent finances using the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.